Monday, April 9, 2012
You visit a patient at home receiving hospice care for cancer. Her pain has been well controlled with long acting morphine 60mg BID and occasional PRN doses of short acting liquid morphine (10mg) over the past few weeks: she had been tolerating this well. She has had recent progressive functional decline and is currently at a PPS of 20%. In the last 24 hours the patient has vomited and has been more lethargic and having difficulty swallowing pills. She appears uncomfortable. In your examination you see a very thin patient who appears to be dying with a prognosis in the few days to a week range.
The patient’s son is a respiratory therapist at a hospital and is insisting you change the patient’s opioid to a fentanyl patch because “it is less sedating than morphine.”
The best response is:
a) Because the patient is cachectic, you tell the family that fentanyl transdermal patches are not indicated because the medication will not be absorbed.
b) Agree with the son and convert the patient to a 37.5mcg/hr fentanyl patch with oral morphine liquid 10mg q1 hour PRN
c) Because the fentanyl will not be effective for over 24 hours, continue the long acting morphine sulfate 60mg BID but give it rectally instead of by mouth
d) Suggest starting a morphine infusion via her port at 1.7mg/hr basal with a 3mg q30min bolus PRN after talking with the son about his concerns about sedation.
Discussion:
Answer and Discussion:
The correct answer is D.
a) Cachexia has not been show to be a CLINICALLY RELEVALANT factor in absorption of transdermal fentanyl. Cachexia will decrease the amount of subcutaneous fat which is where fentanyl is stored AFTER absorption through the dermal layers. In 2009 Heiskanen did a study comparing blood levels between cachectic and non-cachectic volunteers and found no significant difference, although cachectic patients had a slightly lower mean concentration. There was no difference in VAS score.
b) Fentanyl is not less sedating than morphine at equianalgesic doses. Also there is no 37.5mcg/hr patch or 12.5mcg/hr patch. As written, and described by the manufacturer, the “12.5mcg/hr patch” is labeled and Rx’d as a “12mcg/hr” patch to prevent confusion with Rx’ing 125mcg/hr. As for the conversion, it could be acceptable to use a 25mcg/hr & 12mcg/hr patch (total 37mcg/hr) per the Fentanyl transdermal product insert. It recommends 25mcg/hr for someone on OMDD of 60-134mg and 50mcg/hr for someone on OMDD 135-224, so this is right in the middle. The Breitbart/Donner conversion of 2mg morphine = 1mcg/hr transdermal fentanyl which would be 60mcg/hr of fentanyl (You could choose 50 or 75 depending on other clinical circumstances).
c) The pharmacokinetics of fentanyl do not warrant switching to it if otherwise indicated. Morphine still has time to circulate and get out of her system, and fentanyl begins to reach significant blood concentrations 8-12 hours after application. If needed, she can be bridged with a few doses of liquid morphine. In addition, people do not prefer rectal administration if it could be avoided.
d) A morphine continuous infusion allows for the continuation of the current effective opioid in a patient who is likely not going to regain swallowing function. The conversion is most direct (120mg OMDD = 40mg daily IV = 1.7mg/hr (1.5 if your pumps are limited in decimal rates). A 3 mg IV morphine bolus most closely replicates the 10mg oral morphine doses that were effective prior. If you did not choose this answer because your hospice doesn’t use continuous infusions (expense, nurse familiarity, not available from local pharmacy) then start talking with your hospice to decrease these barriers to an effective and essential tool to good pain management.
References:
- Cachexia and Transdermal Abosrption of Fentanyl - Pallimed
- Heiskanen, Tarja. (2009-7) Transdermal fentanyl in cachectic cancer patients. PAIN, 70(1-2), 928-222. DOI: 10.1016/j.pain.2009.04.012
- Mercadante, Sebastiano. (2012-01-09) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain, 7(Suppl. A), 320-1046. DOI: 10.1016/j.ejpain.2008.01.013
- Weissman DE. Converting to/from Transdermal Fentanyl, 2nd Edition. Fast Facts and Concepts. July 2005; 2. Available at: http://www.eperc.mcw.edu/fastfact/ff_002.htm.
- Tatum IV WO. (2002) Adult patient perceptions of emergency rectal medications for refractory seizures. Epilepsy & behavior : E&B, 3(6), 535-538. PMID: 12609248
- Colbert SA, O'Hanlon D, McAnena O, & Flynn N. (1998) The attitudes of patients and health care personnel to rectal drug administration following day case surgery. European journal of anaesthesiology, 15(4), 422-6. PMID: 9699099
- Mercadante, Sebastiano. (2012-01-09) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain, 7(Suppl. A), 320-1046. DOI: 10.1016/j.ejpain.2008.01.013
Previous Blogs to Boards Question (5)
Next Blogs to Boards Question (7)
Monday, April 9, 2012 by Christian Sinclair ·
Monday, April 2, 2012
Mrs Dole, a 68 year old with 20 year history of Diabetes Mellitus Type II is referred to Palliative Care from Oncology with Stage III Nasopharyngeal carcinoma. Nausea is the key concern. For last 3 years she has had early satiety but maintained weight. Since initiating chemotherapy, she has had nausea for the first 2 days of her chemotherapy cycle, which then resolves.
1 week after the last round of chemotherapy she required intravenous fluids for dehydration. Now 2 weeks later is having intermittent severe nausea. It can be provoked by sudden changes in body position. She fell once because she lost her balance. Usually she does not vomit, but occasionally does. She describes a feeling of the room spinning associated with the nausea.
Of the following options, which drug is most targeted to this patient’s specific nausea type:
a) Ondansetron
b) Prochlorperazine
c) Metoclopramide
d) Diazepam
e) Meclizine
Discussion:
Answer and Discussion:
The correct answer is E.
This patient has had multiple types of nausea, however currently her major nausea type seems to be vestibular. She may have developed an otolith while dehydrated. Some chemotherapeutic agents are ototoxic and can cause vestibular symptoms including hearing loss, tinnitus, vertigo/nausea. She also has had chemotherapy induced nausea, as well as diabetic gastroparsis. For the boards, probably the default choice for nausea will be D2 blockers, however there are certain types of nausea for which D2 blockers are not the best choice.
a) Ondansetron and the other ‘-setrons’ are HT3 receptor blockers and have excellent evidence for the treatment of chemotherapy induced nausea, and post-operative nausea. While used widely for other types of nausea including opioid-associated, there is less evidence to support them for these practices. They are exceedingly safe and well-tolerated; they are constipating.
*** Chemotherapy induced nausea/vomiting (CINV) is considered acute when it occurs <24h after chemo infusion, and delayed if >24h. Delayed n/v usually occurs in the several days after chemotherapy, but not weeks. First line treatments to prevent acute CINV including 5HT3 blockers and steroids. NK-1 blockers such as aprepitant and gluclocorticoids are also used, especially for mod-highly emetogenic chemo. NK-1 blockers and steroids also prevent delayed N/V; 5HT3 blockers less so. D2 blockers are no longer first line agents as 5HT3 blockers have clearly shown superior efficacy and safety. Doses of metoclopramide needed to be effective are 1-2mg/kg IV!
b) Prochlorperazine and other D2 blockers such as haloperidol target the Chemoreceptor trigger zone and D2 receptor. They are the work-horses of nausea treatment.
c) While the patient has some component of diabetic gastroparesis suggested by satiety and long history of DM, he is not bothered by emesis with meals. Metoclopramide targets D2 receptors primarily in the gut, and has some prokinetic features, but its role long-term for gastroparesis is controversial as it causes EPS such as tardive dyskinesia.
d) Diazepam and benzodiazepines are effective for anticipatory nausea/vomiting which occurs in ~25% of chemo patients. Behavorial/cognitive treatments, and integrative modalities are probably helpful too. Aggressive prevention of CINV can help prevent anticipatory n/v.
She has what seems to be vestibular symptoms. Anticholinergic drugs such as meclizine, scopolamine, promethazine, and even diphenhydramine are potential drugs. CNS side effects such as sedation, confusion; as well as orthostatis and xerostomia are worrisome side effects.
References:
- Wood et al. Management of Intractable Nausea and Vomiting in Patients at the End of Life. JAMA. 2007;298(10):1196-1207
- Vatican on Tube Feeding, More on Abigail, Nausea Review in JAMA - Pallimed
- Hain TC, Uddin M. Pharmacological treatment of vertigo. CNS Drugs. 2003;17:85–100.
Previous Blogs to Boards Question (3)
Next Blogs to Boards Question (5)
Monday, April 2, 2012 by Christian Sinclair ·
Sunday, April 1, 2012
(We hope you enjoyed our April Fool's jokes this year. Look for more of our past April Fool's posts here. - Ed.)
| Leaders of the APRIL-FUL showing good bedside manner |
Explaining the historic cooperation between ACGMC and AVMA COC, ACGMC board chairman Dr. Moe Howard said "the recent change in the specialty's name presented an opportunity for strategic cooperation between our two organizations that we couldn't pass by. Working together, we can fulfill our mission to assure the public that graduates of HPMP training programs are fully competent to carry out all the duties of an HPCP specialist, including finding the right type of puppy to meet a patient and families needs."
- one month rotation at a veterinary hospital accredited by AVMA COC
- six month continuity clinic at a PetSmart or other similar community-based pet training center
- inclusion of a pet therapist (the pet, not the person) at all IDT team meetings that the trainee attends
- a scholarly project documenting impact of puppies on palliative care patients or staff or volunteers
When asked for comment, the National Association for Cats in Hospice issued a statement declaring, "We would rather work on our own and not be dependent on any other organizations like some sniveling canine."
Happy April Fools Day 2012 from Pallimed
Sunday, April 1, 2012 by Abe R Feaulx ·
To the cheers of supporters, aides to Generalissimo Francisco Franco announced that the Generalissimo has received a left ventricular assist device, also known by the abbreviation, LVAD. The procedure was performed at an undisclosed location. At this time, it is uncertain how this development will ultimately affect the Generalissimo's fate. Aides declined to comment on whether the Generalissimo would be placed on a heart transplant list.
At this time Generalissimo Francisco Franco is not dead.
Stay tuned for further updates.
by Abe R Feaulx ·
(We hope you enjoyed our April Fool's jokes this year. Look for more of our past April Fool's posts here. - Ed.)
April 1, 2012
by Abe R Feaulx, Pallimed Special Reporter
On a cross-country plane flight, Dr. Arya Kidenmee finally admitted to her seatmate, an unabashedly handsome young shower curtain salesman, what the public has known all this time. "I finally had to tell him that hospice work is very sad. I'm not sure why people in hospice and palliative care always say it is rewarding. We have meetings every week where we just sit and cry the entire time, it is absolutely emotionally paralyzing to try and help people with advanced illness."
When reached for comment, seatmate Brock Montgomery noted, "I knew it. I run into people in health care all the time and people who work for hospice always appear so friendly and outgoing, but I knew there could not be anything rewarding in helping people who were in great pain feel better. I'm glad she finally told the truth."
Dr. Kidenmee noted that she has struggled for years in talking at dinner parties and other social gatherings when asked about what she does for a living. "If only I could take people with me and show them how utterly sad my everyday job is, then maybe they would understand that research that shows resilience and a strong purpose to work in palliative care was all a bunch of baloney. Yes I said it, baloney."
Update: It was later discovered after this story was published that Dr. Arya Kidenmee is not really a physician and clearly from her comments has no experience in hospice. She was just trying to get Brock to feel bad for her and ask for her number.
Happy April Fools Day 2012 from Pallimed
by Abe R Feaulx ·
Monday, March 26, 2012
Walking into a room at your hospice inpatient unit you see a tired appearing female patient lying in bed with soft moaning, holding her abdomen. She has end stage CHF and no history of cancer. Review of your notes show decreasing oral intake and increased time in bed. Her nurse reports she disimpacted her yesterday after suppositories and enemas were ineffective for worsening constipation.
Medications include: Fentanyl 50mcg patch (on for several weeks), Senna 2 tabs BID, Colace daily, Recent enema, and docusate suppository
Exam: Cachectic female, Scaphoid abdomen, hypoactive bowel sounds, formed (but not hard) stool on rectal exam.
What is the next best step?
a) Write an order for methylnaltrexone 8mg subcutaneously x1 now.
b) Switch her from a fentanyl patch to a morphine pump so you can better manage her abdominal pain.
c) Write an order for octreotide 200mcg subcutaneously twice daily for three days.
d) Place an NG and give her polyethylene glycol daily until she has a bowel movement or regains ability to swallow and you can remove the NG tube
Discussion:
Answer and Discussion:
The correct answer is A
a) The patient likely has opioid induced constipation (OIC). Methylnaltrexone is a mu-opioid receptor antagonist and is related to naloxone. After ruling out bowel obstruction, fecal impaction and any other abdominal process, you give methylnaltrexone at 0.15mg/kg subcutaneously, usually 8 (patients < 136lbs) or 12 mg (patients over 136lbs). About 60 percent of patients will have a BM in under 4 hours. Usually within 30 minutes of the first dose. Number needed to treat was 2.2 (pretty darn good). One barrier is cost. At $48 per 8mg dose this is a costly way to manage constipation.
b) While controlling abdominal pain is important relieving the cause of the abdominal pain takes precedence. Opioids may be the cause of her pain – increasing them is not indicated. With the exception of imminently dying patients, proper treatment of OIC will lead to its resolution and function can be improved.
c) Octreotide has a role in palliative care for malignant bowel obstruction (MBO), not constipation. This patient does not have a cancer history and sudden onset nausea and vomiting that may be signs for a MBO. Octreotide also is expensive-costing between $40 and $80 per dose.
d) Placing a nasogastric tube should be avoided whenever possible when there are less invasive measures available. The patient can swallow oral laxatives, and does not have an MBO and so does not have any minimal indications for an NGT in any case. Polyethylene glycol is helpful as an osmotic laxative and is often employed as a first line option for OIC. It is often more helpful as part of a maintenance regimen or for mild to moderate constipation.
References:
- Thomas, Jay et. al. Methylnaltrexone for Opioid Induced Constipation in Advanced Illness. 2008. NEJM 358 (22): 2332-2343.
- Yuan, Chun-Su. Methylnaltrexone Mechanisms of Action and Effects on Opioid Bowel Dysfuction and Other Opioid Adverse Side Effects. The Annals of Pharmacotherapy, 2007. 41: 984- 993
(For email readers - click here for full post to see the answer and discussion)
Monday, March 26, 2012 by Christian Sinclair ·
Thursday, March 8, 2012
If you didn't get the chance to attend, don't fret. We plan to post a question a week on both GeriPal and Pallimed to get everyone ready of the 2012 palliative care boards.
Thursday, March 8, 2012 by Christian Sinclair ·
Wednesday, March 7, 2012
Tarantula Billiards Bar and Grill is one block away from the convention center. The address is 1520 Stout St. Denver, CO.
The party is open to all, so drop on by.

Wednesday, March 7, 2012 by Brian McMichael, M.D. ·
Wednesday, February 8, 2012
Wednesday, February 8, 2012 by Brian McMichael, M.D. ·
Friday, February 3, 2012
World Cancer Day is February 4th, and in honor of this day, I'm posting about a critical issue we have written about on Pallimed before... access to medications. There are three developments in the last few days I think are worth knowing about...
Friday, February 3, 2012 by Holly Yang, MD ·




